Share Email Print

Proceedings Paper

Interstitial laser immunotherapy for treatment of metastatic mammary tumors in rats
Author(s): Daniel Figueroa; Chet Joshi; Roman F. Wolf; Jonny Walla; Jessica Goddard; Mallory Martin; Stanley D. Kosanke; Fred S. Broach; Sean Pontius; Destiny Brown; Xiaosong Li; Eric Howard; Robert E. Nordquist; Tomas Hode; Wei R. Chen
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Thermal therapy has been used for cancer treatment for more than a century. While thermal effect can be direct, immediate, and controllable, it is not sufficient to completely eradicate tumors, particularly when tumors have metastasized locally or to the distant sites. Metastases are the major cause of treatment failure and cancer deaths. Current available therapies, such as surgery, radiation, and chemotherapy, only have limited curative effects in patients with late-stage, metastatic cancers. Immunotherapy has been considered as the ultimate approach for cancer treatment since a systemic, anti-tumor, immunological response can be induced. Using the combination of photothermal therapy and immunotherapy, laser immunotherapy (LIT),a novel immunotherapy modality for late-stage cancer treatment, has been developed. LIT has shown great promise in pre-clinical studies and clinical breast cancer and melanoma pilot trials. However, the skin color and the depth of the tumor have been challenges for effective treatment with LIT. To induce a thermal destruction zone of appropriate size without causing thermal damage on the skin, we have developed interstitial laser immunotherapy (ILIT) using a cylindrical diffuser. To determine the effectiveness of ILIT, we treated the DMBA-4 metastatic tumors in rats. The thermal damage in tumor tissue was studied using TTC immersion and hematoxolin and eosin (H & E) staining. Also observed was the overall survival of the treated animals. Our results demonstrated that the ILIT could impact a much larger tumor area, and it significantly reduced the surface damage compared with the early version of non-invasive LIT. The survival data also indicate that ILIT has the potential to become an effective tool for the treatment of deeper, larger, and metastatic tumors, with reduced side effects.

Paper Details

Date Published: 23 February 2011
PDF: 11 pages
Proc. SPIE 7900, Biophotonics and Immune Responses VI, 79000A (23 February 2011); doi: 10.1117/12.873925
Show Author Affiliations
Daniel Figueroa, Univ. of Central Oklahoma (United States)
Chet Joshi, Univ. of Central Oklahoma (United States)
Roman F. Wolf, The Univ. of Oklahoma Health Sciences Ctr. (United States)
Jonny Walla, Univ. of Central Oklahoma (United States)
Jessica Goddard, Univ. of Central Oklahoma (United States)
Mallory Martin, Univ. of Central Oklahoma (United States)
Stanley D. Kosanke, The Univ. of Oklahoma Health Sciences Ctr. (United States)
Fred S. Broach, The Univ. of Oklahoma Health Sciences Ctr. (United States)
Sean Pontius, Univ. of Central Oklahoma (United States)
Destiny Brown, Univ. of Central Oklahoma (United States)
Xiaosong Li, Univ. of Central Oklahoma (United States)
First Affiliated Hospital of Chinese PLA General Hospital (China)
Chinese PLA General Hospital (China)
Eric Howard, The Univ. of Oklahoma Health Sciences Ctr. (United States)
Robert E. Nordquist, Immunophotonics, Inc. (United States)
Tomas Hode, Immunophotonics, Inc. (United States)
Wei R. Chen, Univ. of Central Oklahoma (United States)

Published in SPIE Proceedings Vol. 7900:
Biophotonics and Immune Responses VI
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top